| Name | Title | Contact Details |
|---|
Alvarez Stauffer Bremer PLLC is a full service law firm, located in downtown Houston, specializing in Pre-Litigation Disputes, Commercial Litigation, Energy Litigation, Mass Tort and Catastrophic Incident Litigation, Arbitration, and eDiscovery. ASB proudly represents international energy companies, large health-care and hospital systems, and pipeline operators — not to mention individuals and closely held companies.
ChoiceOne Bank is a community bank holding company based in Michigan, with approximately $2.6 billion in assets. Founded in 1898 as Sparta State Bank, it has grown through strategic mergers and now operates 35 offices across multiple counties. The bank is headquartered in Sparta and has operations centers in Lapeer and Fenton, ensuring efficient service delivery. ChoiceOne offers a wide range of financial services, including digital banking solutions, consumer and commercial banking, agricultural lending, mortgage services, wealth management, payroll solutions, and treasury management. The bank is dedicated to serving a diverse customer base, including families, small businesses, farmers, and low-income individuals, particularly in rural communities. ChoiceOne is committed to being an integral part of Michigan communities, with a mission to provide superior service and quality advice. In 2025, the bank announced a merger with Fentura Financial Inc., enhancing its presence in the Detroit suburbs and expanding into the Flint and Saginaw markets.
Nobu, the world-renowned Japanese restaurant recognized for pioneering a new-style Japanese cuisine, started as a business partnership in 1994 between Chef Nobu Matsuhisa and his partners, Academy Award-winning actor Robert De Niro, producer Meir Teper, and restaurateur Drew Nieporent. Originating in New York as the flagship restaurant, the Nobu brand is now an empire that spans five continents with over 40 restaurants and growing. Following the success of the restaurants, Nobu Hospitality opened the first Nobu Hotel in 2013 in Las Vegas and today has 13 hotels open with several more in development.
SMSI is a small business providing management and technical/engineering services to the DOE/NNSA, national laboratories, and industrial clients. Our work with nuclear facility operations and safety has set the standard for excellence. We are the resource for highly technical engineering and nuclear safety basis development, review, and implementation at the national laboratories. SMSI has a demonstrated record of success providing superior people developing and implementing innovative solutions, delivering projects on time and within budget. We build productive relationships by being highly responsive to our customers. Operations began in 2000 with headquarters in Albuquerque, NM, and currently operating offices in Los Alamos, NM and Oak Ridge, TN.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.